Eye-opening discovery about adult brain’s ability to recover vision
UCI team demonstrates the adult brain has the potential to partially recover from inherited blindness.
In the cockpit: Schallhorn recounts his time as a Top Gun pilot
One of the country’s leading ophthalmologists, Steven Schallhorn, MD, says his life and career have been shaped by his time as a Navy pilot in the elite Top Gun program.
Surrozen announces partnership with Boehringer Ingelheim to develop Wnt agonist SZN-413 for people diagnosed with retinal diseases
Surrozen Inc. announced this week that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for the treatment of retinal diseases.
Paladin Phase 4 study confirms fluocinolone acetonide intravitreal implant patients' reduced need for multiple treatments
Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented at the annual American Academy of Ophthalmology’s 2022 annual conference in Chicago.
Study casts doubt on routine use of anesthesiologists in cataract surgery
According to investigators, ophthalmologists may be able to safely cut back on having anesthesiologists or nurse anesthetists routinely at bedside during cataract surgery.
Visiox Pharma submits NDA seeking approval for first once-daily brimonidine for glaucoma
Visiox Pharma has announced the submission of a New Drug Application to the FDA for lead product candidate, PDP-716.
Researchers discover new molecular driver of retinoblastoma
Children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Researchers at UT Southwestern and the University of Miami have discovered that a molecule – estrogen-related receptor gamma, or ESRRG – becomes hyperactive and promotes tumor cell survival in retinoblastoma.
AI-enabled imaging of retina’s vascular network can predict cardiovascular disease/death
New research paves the way for accurate non-invasive screening test that doe not have to be done in the clinic.
Myze launches platform to engage 1 million dry eye patients by 2025: How Do Your Eyes Feel?
Leading U.S. eye care experts advance eye health focused digital platform designed to make eye care part of daily self-care routine.
Assessing the effectiveness of netarsudil and episcleral blood flow in treatment-naive glaucoma suspects, hypertension subject
Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."
Higher rates of repeat corneal crosslinking need found in younger patients
At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.
Choosing among DSAEK, DMEK and DSO for endothelial keratoplasty
Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"
Post hoc analysis of varenicline solution OC-01 shows promise for dry eye patients undergoing anticholinergic therapy
At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."
AAO: Janssen announces late-breaking data from a pair of gene therapy programs
In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Positive visual outcomes reported one year following monocular implantation of small aperture IOL
Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.
Reviewing the AAO cornea preferred practice patterns: Corneal edema, opacifications, ectasia and bacterial keratitis
David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.
Donation bolsters Vanderbilt’s work in retinal vision research
According to a Vanderbilt University news release, the International Retinal Research Foundation has extended a $10 million gift to establish a center dedicated to retinal vision research at the Vanderbilt Eye Institute and a directorship to support a physician-scientist leader in the Department of Ophthalmology and Visual Sciences.
Apellis announces 24-month Phase 3 study of pegcetacoplan for GA
Data were presented during an oral presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago.
Study: Eyenuk artificial intelligence detects diabetic retinopathy with more sensitivity than dilated exams
Academic leaders will review their experience with the technology during a symposium at the American Academy of Ophthalmology annual meeting, being held at McCormick Place in Chicago.
Tarsus kicks off ‘Look at the Lids’ campaign to encourage eye care professionals to Identify, diagnose Demodex blepharitis
During the American Academy of Ophthalmology 2022 Annual Meeting in Chicago,Tarsus Pharmaceuticals Inc. announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis.
Dispersive ophthalmic viscosurgical device found to be safe, effective in clinical trials
Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."
Visus Therapeutics CEO announces acquisition of ViewPoint Therapeutics to expand on cataract, presbyopia candidate
Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
CXL Ophthalmics publishes results of Phase 2 clinical trial for keratoconus
CXL Ophthalmics Inc. on Thursday published results of the EpiSmart cross-linking Phase 2 study for keratoconus.
California governor vetoes bill that would have reduced licensing requirements to perfom eye surgery
AB 2236 would have allowed optometrists to perform anterior segment laser and minor procedures which involve the use of a scalpel or injections.
ImprimisRx launches compounded Antibiotic Formulation
Visus Therapeutics expands ophthalmic drug development portfolio with acquisition of ViewPoint Therapeutics' assets
Library of ViewPoint drug candidates will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
Presbyopia-correcting IOL on display at AAO
At the American Academy of Ophthalmology in Chicago, Johnson & Johnson Vision is spotlighting the Tecnis Symfony OptiBlue IOL, its presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology.
Ophthalmologists may be bucking the trend in a recent study on physician burnout
The survey, from The Larry A. Greene Center and the Primary Care Collaborative, found that the COVID-19 pandemic has had an adverse impact on the well-being of physicians.
2 Clarke Drive Cranbury, NJ 08512